Global Polycystic Ovary Syndrome Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

1. Polycystic
Ovary
Syndrome
Market
Global Polycystic Ovary Syndrome Market, Size, Share, Market
Intelligence, Company Profiles, Market Trends, Strategy, Analysis,
Forecast 2018-2023
https://www.omrglobal.com/industry-reports/polycystic-ovary-syndrome-market/

2. Polycystic ovary syndrome market is a
hormonal disorder observed in females of
reproductive ages. The disorder causes
the excessive production of hormones in
the female body, which include
testosterone or androgens, hormones that
are primarily associated with the male
reproductive system.

3. PCOS includes a range of symptoms
such as irregular menstrual cycle,
trouble in getting pregnant, cyst
formation in the ovaries, excessive body
and facial hair, and pelvic pain, among
others.

4. Moreover, the early diagnosis of the
disorder is highly recommended by the
physicians, as untreated PCOS may
often lead to high cholesterol, type-2
diabetes, heart disease, insulin
resistance, and high blood pressure.

5. Major factors contributing to the
growth of the global polycystic ovary
syndrome market include sedentary
lifestyle and faulty dietary habits and
increasing female obese population
across the globe.

6. Initiatives taken by the government
and non-profit organizations to spread
awareness regarding the early
diagnosis of the disorder is
significantly fueling the market
growth.

7. Moreover, increasing genetic and
hormonal disorder in female
population is a major cause for the
increase of polycystic ovary syndrome
patients across the globe.

8. Lack of regulatory approved drugs for
the treatment of PCOS and easy
availability of generic and off-label
drugs may restrain the growth of the
global PCOS market.

9. However, market players are focusing
in the development of innovative and
symptom specific drugs are expected to
fuel the market growth in the near
future.

10. The polycystic ovary syndrome
market can be segmented on the
basis of drug type, diagnosis type,
treatment type, and distribution
channel. Based on drug type, the
market is segmented into diuretics,

11. Insulin sensitizing agents,
antiandrogens, anti-depressants,
ornithine decarboxylase inhibitors,
anti-obesity, and oral contraceptive
pills. Based on diagnosis type, the
market is bifurcated into ultrasound,
pelvic exam, and blood tests. Based on
treatment type,

12. The market is segmented into ovarian
wedge resection, laparoscopic ovarian
drilling, and acupuncture. Based on
distribution channel, the market is
diversified into hospital pharmacies,
drug stores, retail pharmacies,

13. fertility clinics, and e-commerce.
Among type of drugs, the insulin-
sensitizing agents segment holds a
major share in the polycystic ovary
syndrome market. This is owing to
wide adoption of the drug for the
treatment of insulin resistance, to
prevent diabetes.

14. The global polycystic ovary syndrome
market is further analyzed on the basis of
the geographical regions that are
contributing significantly towards the
growth of the market. North America
holds a dominant position in the global
polycystic ovary syndrome market,
followed by Europe.

15. This is mainly owing to sedentary lifestyle
of the people leading to high prevalence of
disorder in the region. High
reimbursement policies by the
government in the healthcare sector and
awareness amongst the population
regarding the early diagnosis of the
disorder are significantly contributing
towards the market growth in the region.

16. Asia Pacific is projected to exhibit
fastest growth in the global polycystic
ovary syndrome market over the
forecast period. This is due to large
pool of female obese population in the
region, especially in China.

17. Some of the key players operating in
the global polycystic ovary syndrome
market are Abbott Laboratories, Bayer
AG, AstraZeneca, Novartis,
Glaxosmithkline plc, Teva
Pharmaceuticals, and Furocyst, among
others.

18. In order to sustain in the competitive
market, these players adopt various
strategies such as Acquisitions,
mergers, expansions, joint ventures and
product development and so on. For
instance, in April, 2017,

19. Astellas Pharma announced the
acquisition of Ogeda SA, a Europe-based
drugmaker. Through acquisition, Astellas
will develop solutions for alleviating
menopause without hormonal therapy.
Moreover, the deal includes treatment
trials of Phase II testing for polycystic
ovary syndrome and uterine fibroids.

20. The market study of polycystic ovary
syndrome market is incorporated by
extensive primary and secondary
research conducted by research team at
OMR.
Research Methodology

21. Secondary research has been
conducted to refine the available data
to breakdown the market in various
segments, derive total market size,
market forecast and growth rate.

22. Different approaches have been
worked on to derive the market value
and market growth rate. Our team
collects facts and data related to the
market from different geography to
provide a better regional outlook.

23. In the report country level analysis is
provided by analyzing various regional
players, regional tax laws and policies,
consumer behavior, and macro-economic
factors. Numbers extracted from secondary
research have been authenticated by
conducting proper primary research. It
includes tracking down key people from the
industry and interviewing them to validate
the data.

24. This enables our analyst to derive the
closest possible figures without any
major deviations in the actual number.
Our analysts try to contact as many
executives, managers, key opinion
leaders and industry experts. Primary
research brings the authenticity in our
reports.

25. • Whitepapers, research-papers, and
news blogs
• Company websites and their product
catalogue.
Secondary Sources Include

26. • Financial reports of companies
involved in the market
• Authentic Public Databases such as
PCOSAA, American College of
Obstetricians and Gynecologists,
womenshealth.gov, and others
• Supplier Websites such as Alibaba,
amazon for pricing analysis.

27. The report is intended for drug
manufacturers, healthcare provider,
government organizations for overall
market analysis, and competitive analysis.
The report provides in-depth analysis on
pricing, market size, intended quality of
the product preferred by consumers,
initial norms and vehicle segment

28. The report will serve as a source for
360-degree analysis of the market
thoroughly integrating different models
such as PEST analysis, Porter five
analysis delivering insights into the
market for better business decisions.

29. •
•Global polycystic ovary syndrome market
is segmented on the basis of regional
outlook and following segments:
• Global Polycystic Ovary Syndrome
Market Research and Analysis, By Drug
Type
• Global Polycystic Ovary Syndrome
Market Research and Analysis, By
Diagnosis Type
Market Segmentation

30. • Global Polycystic Ovary Syndrome
Market Research and Analysis, By
Treatment Type
• Global Polycystic Ovary Syndrome
Market Research and Analysis, By
Distribution Channel
• Global Polycystic Ovary Syndrome
Market Research and Analysis, By
Region

31. • Comprehensive research methodology
of global polycystic ovary syndrome
market.
• This report also includes detailed and
extensive market overview with key
analyst insights.
THE REPORT COVERS

32. • Exhaustive analysis of macro and micro
factors influencing the market guided by
key recommendations.
• Analysis of regional regulations and
other government policies impacting the
global polycystic ovary syndrome market.
• Insights about market determinants
which are stimulating the global
polycystic ovary syndrome market.

33. • Detailed and extensive market
segments with regional distribution of
forecasted revenues.
• Extensive profiles and recent
developments of market players.

34. CONTACT US
+1-646-755-7667
+91-7803040404
info@omrglobal.com
Orion Market Research Pvt. Ltd. (OMR Global) 116, Shagun Arcade,
Indore, Madhya Pradesh India- 452010
www.omrglobal.com/
https://www.omrglobal.com/industry-reports/polycystic-ovary-syndrome-market/